Dr. Joppert is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3850 Tampa Rd
Suite 202
Palm Harbor, FL 34684Phone+1 727-784-6779Fax+1 727-781-8910
Education & Training
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 1994 - 1997
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 1988 - 1991
Faculdade de Medicina da Universidade Federal do Rio de JaneiroClass of 1983
Certifications & Licensure
OH State Medical License 1996 - 2026
UT State Medical License 1995 - 2026
FL State Medical License 1997 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011
Clinical Trials
- A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer Start of enrollment: 2005 Oct 01
Publications & Presentations
PubMed
- 9 citationsA phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancerMarcos G. Joppert, D.H Garfield, M.A Gregurich, J.J Nemunaitis, Thomas A. Marsland
Lung Cancer. 2003-02-01 - 2 citationsTopoisomerase I-based nonplatinum combinations in non-small-cell lung cancerCaio Max S. Rocha Lima, Marcos G. Joppert
Oncology. 2002-09-02 - 12 citationsResults of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.Marcus A. Neubauer, Craig H. Reynolds, Marcos G. Joppert, Thomas Whittaker, Habib M. Ghaddar
Clinical Lung Cancer. 2005-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
